Nancy Lewis - Concepedia

Author

Nancy Lewis

Also Known As

Lewis, Nancy, N L LEWIS, N L Lewis, N Lewis, N. L. Lewis, N. Lewis, N.L. Lewis, Nancy L Lewis, Nancy L. Lewis, Nancy Lewis

Publications

Citations

H-Index

Concepts

All Affiliations

Fox Chase Cancer Center Thomas Jefferson University The University of Texas MD Anderson Cancer Center Geriatric Research Education and Clinical Center University of California, Los Angeles

About

Nancy Lewis is an author at Fox Chase Cancer Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	25	1.4K
2	Health Sciences	3	3	160
3	Public Health	2	2	92
4	Social Sciences	2	2	105
5	Applied Physiology	1	1	29

Nancy Lewis

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G<sub>1</sub> Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 Jennifer L. Spratlin, Roger B. Cohen, Matthew Eadens, Journal of Clinical Oncology	2010	551
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Funda Meric‐Bernstam, Randy F. Sweis, F. Stephen Hodi, Clinical Cancer Research	2021	328
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study Funda Meric‐Bernstam, Randy F. Sweis, Stefan Kasper, Clinical Cancer Research	2022	205
Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer Steven J. Cohen, R. Katherine Alpaugh, Steve Gross, Clinical Colorectal Cancer OncologyMedicineCirculating Tumor CellsBiological MicroenvironmentsColorectal Cancer	2006	188
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. Funda Meric‐Bernstam, Shahneen Sandhu, Omid Hamid, Journal of Clinical Oncology ImmunologyImmunoeditingPathologyImmunotherapeuticsInterferon Genes	2019	186
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours M. Cianfrocca, Kathryn A. Kimmel, James M. Gallo, British Journal of Cancer	2006	173
Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma Steven J. Cohen, Linus Ho, Sulabha Ranganathan, Journal of Clinical Oncology	2003	169
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh, Annals of Oncology Advanced EsophagealSurgical OncologyEsophagusEsophageal CancerGastroesophageal Junction	2016	143
Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients Kevin M. Koch, Nandi J. Reddy, Roger B. Cohen, Journal of Clinical Oncology	2009	138
Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers Nancy Lewis, Lionel D. Lewis, Joseph P. Eder, Journal of Clinical Oncology	2009	92

Page 1